Literature DB >> 11556751

Antigenic characterization of medullary carcinoma of the breast: HLA-DR expression in lymph node positive cases.

B Lazzaro1, A E Anderson, A Kajdacsy-Balla, M J Hessner.   

Abstract

Medullary carcinoma of the breast has attracted attention because of its relatively good prognosis, in spite of its high cytologic grade. It has, by definition, a consistent, florid tumor infiltrating lymphocyte (TIL) population, probably the result of cytotoxic T-lymphocytes recognizing tumor cells in an HLA-DR-restricted manner. HLA-DR tends to be more highly expressed on primary medullary carcinoma cells than on ductal carcinoma cells; however, the MHC-class II antigenicity of the tumor cells themselves has not been analyzed extensively, and as yet there has been no comparative study of HLA-DR expression in medullary and ductal carcinomas metastatic to lymph nodes. Eleven cases of medullary carcinoma and 15 cases of ductal carcinoma, primaries, and respective lymph node metastases were analyzed by immunoperoxidase staining for HLA-DR and lymphocytes antigens. Polymerase chain reaction (PCR) analysis to identify HLA-DR subtypes from the paraffin blocks was performed on selected cases of primaries and nodal metastases of both tumor types. Immunoperoxidase staining for HLA-DR antigen revealed a marked difference in antigen expression between medullary and ductal carcinomas. In the medullary carcinomas, the mean percentage of cells staining for HLA-DR was 74.5% in the primary tumors and 67.3% in the nodal metastases. For the ductal carcinomas, the mean percentage of cells staining was 17.7% in the primaries and 7% in the metastases. There was a tendency for the level of HLA-DR expression to remain high in medullary carcinoma metastatic to nodes, whereas whatever HLA-DR was present within ductal primaries tended to diminish when cells metastasized to regional nodes. PCR analysis of the HLA-DR within the two tumor types revealed no emerging subtype or variant that could be associated with either the medullary or the ductal carcinomas. Medullary carcinoma cells express much greater quantities of HLA-DR, on the whole, than ductal carcinomas. Expression of HLA-DR is retained on medullary carcinoma cells that have spread to lymph nodes, whereas the smaller quantities of HLA-DR present within ductal primaries tend to diminish even further when the tumor cells are found in lymph nodes. No discernible HLA-DR mutations or predominant subtypes emerged on PCR analysis, and the authors therefore conclude that it is the quantity and not the quality of HLA-DR expression in medullary carcinoma that maintains the characteristic TIL infiltrate, not seen in ductal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556751     DOI: 10.1097/00129039-200109000-00007

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  11 in total

1.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

2.  Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.

Authors:  Peter Simsa; Jean-Luc Teillaud; David I Stott; József Tóth; Beatrix Kotlan
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

Review 3.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

4.  HLA class-II allele frequencies in Turkish breast cancer patients.

Authors:  Faik Deniz Gun; Ozlem Goruroglu Ozturk; Ayse Polat; Gurbuz Polat
Journal:  Med Oncol       Date:  2011-03-04       Impact factor: 3.064

5.  The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.

Authors:  Xiangyu Ma; Mengjie Zhao; Zhuo-Xun Wu; Jingfang Yao; Lei Zhang; Jinhong Wang; Zhenbo Hu; Liuya Wei; Zhe-Sheng Chen
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

6.  CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Authors:  P S Zeiner; J Zinke; D J Kowalewski; S Bernatz; J Tichy; M W Ronellenfitsch; F Thorsen; A Berger; M T Forster; A Muller; J P Steinbach; R Beschorner; J Wischhusen; H M Kvasnicka; K H Plate; S Stefanović; B Weide; M Mittelbronn; P N Harter
Journal:  Acta Neuropathol Commun       Date:  2018-03-01       Impact factor: 7.801

7.  Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment.

Authors:  Hao Wang; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Juan Deng; Caicun Zhou; Yayi He
Journal:  Onco Targets Ther       Date:  2019-09-05       Impact factor: 4.147

8.  Spatially-resolved quantification of proteins in triple negative breast cancers reveals differences in the immune microenvironment associated with prognosis.

Authors:  Rachel L Stewart; Anna P Matynia; Rachel E Factor; Katherine E Varley
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

9.  Comprehensive Analysis of Regulatory Network for LINC00472 in Clear Cell Renal Cell Carcinoma.

Authors:  Shuoze Gao; Zhiping Wang
Journal:  J Healthc Eng       Date:  2021-06-09       Impact factor: 2.682

10.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.